DDInter624 DDInter822
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Amprenavir
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glasdegib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Arsenic trioxide
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Glasdegib
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound) and Escitalopram may lead to a major life threatening interaction when taken with Glasdegib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Arsenic trioxide (Compound) and Arsenic trioxide may lead to a major life threatening interaction when taken with Glasdegib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Glasdegib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may lead to a major life threatening interaction when taken with Glasdegib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Glasdegib